South and Central America Cancer Targeted Therapy Market Report Outlook (2021–2031)

The South and Central America Cancer Targeted Therapy Market size is expected to reach US$ 10,151.9 million by 2031 from US$ 4,725.4 million in 2024. The market is estimated to record a CAGR of 11.6% from 2025 to 2031.

Executive Summary and South and Central America Cancer Targeted Therapy Market Analysis:

The South and Central America cancer targeted therapy market is witnessing steady growth, driven by rising cancer incidence, increasing healthcare investments, and growing adoption of precision oncology in major urban centers. The region includes countries such as Brazil, Mexico, Argentina, Colombia, Chile, and Peru, each with distinct healthcare infrastructure, regulatory environments, and economic dynamics influencing market adoption.

Targeted therapies—including monoclonal antibodies, tyrosine kinase inhibitors, immune checkpoint inhibitors, cancer vaccines, and gene therapies—are gradually being integrated into standard oncology practice. Adoption is concentrated in metropolitan areas where advanced hospitals, oncology centers, and diagnostic labs are available. Hospital pharmacies are the primary distribution channel due to the complexity of therapy administration, although retail and specialty pharmacies are expanding access to oral targeted therapies.

Pharmaceutical companies are actively partnering with regional hospitals, government programs, and local distributors to improve accessibility. National cancer programs and government incentives in countries such as Brazil and Mexico support the integration of advanced cancer therapies, although cost and reimbursement remain significant challenges. Clinical trial networks in the region facilitate early access to novel therapies, particularly in urban hospitals.

The South and Central America market presents opportunities for global pharmaceutical companies through localized strategies, expansion of precision oncology initiatives, and education programs for healthcare providers, making it an emerging but high-potential market for targeted cancer therapies.

South and Central America Cancer Targeted Therapy Market - Strategic Insights:

South and Central America Cancer Targeted Therapy Market Segmentation Analysis:

Key segments that contributed to the derivation of the South and Central America Cancer Targeted Therapy market analysis are therapy type, indication, and distribution channel.

• By therapy type, the cancer targeted therapy market is segmented into monoclonal antibodies, tyrosine kinase inhibitors, immune checkpoint inhibitors, cancer vaccines, gene therapy, and others. The monoclonal antibodies segment dominated the market in 2024.
• Based on indication, the cancer targeted therapy market is segmented into blood cancer, lung cancer, breast cancer, colorectum cancer, prostate cancer, stomach cancer, cervical cancer, liver and intrahepatic bile duct cancer, thyroid cancer, and other indications. The lung cancer segment dominated the market in 2024.
• In terms of distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online stores. The hospital pharmacies segment dominated the market in 2024.

South and Central America Cancer Targeted Therapy Market Drivers and Opportunities:

Cutting-Edge Genomic Profiling and Biomarker Research

Advancements in genomic profiling and biomarker discovery are critical market drivers. Technologies such as next-generation sequencing (NGS), liquid biopsy, and molecular diagnostics enable the identification of mutations such as EGFR, ALK, HER2, BRAF, and PIK3CA. These technologies allow precision-guided therapy, enhancing efficacy and minimizing adverse effects.

The adoption of these technologies is concentrated in urban hospitals and academic medical centers in Brazil, Mexico, and Argentina, supported by local investments and international partnerships. Clinical integration of biomarker-driven therapy selection enables oncologists to administer monoclonal antibodies, tyrosine kinase inhibitors, and immune checkpoint inhibitors to patients who are most likely to benefit.

Liquid biopsy adoption allows for disease monitoring, early detection of treatment resistance, and identification of minimal residual disease, improving patient outcomes. Regional genomic initiatives and collaborations with global pharmaceutical companies accelerate the identification of targetable mutations and expand eligible patient populations.

Although cost and access challenges remain in rural areas, government programs and public-private partnerships are gradually expanding infrastructure. Increasing insurance coverage for high-cost therapies, combined with international collaborations, ensures broader adoption of precision oncology. Collectively, advancements in genomic profiling and biomarker discovery are enabling more personalized, effective, and accessible cancer treatment in South and Central America.

Personalized Therapies for Rare Genetically Driven Tumors

The expansion of targeted therapies into rare cancers represents a significant market opportunity. Historically, rare cancers have limited treatment options due to small patient populations, high development costs, and restricted access to therapies. Advances in genomic profiling allow detection of actionable mutations—such as NTRK fusions, RET rearrangements, BRAF, and FGFR alterations—enabling tumor-agnostic therapies for multiple cancer types.

Urban hospitals and oncology centers in Brazil, Mexico, and Argentina are participating in clinical trials for mutation-driven therapies, supported by partnerships with global pharmaceutical companies such as Roche, Merck, AstraZeneca, Novartis, and Bristol-Myers Squibb. Basket and umbrella trial designs allow simultaneous evaluation of therapies across rare tumor types, reducing development timelines and facilitating regulatory approvals.

Orphan drug designations and accelerated regulatory pathways in countries such as Brazil and Mexico encourage pharmaceutical companies to invest in rare cancer therapeutics. Early adoption of novel therapies in metropolitan hospitals and academic centers improves patient outcomes while demonstrating commercial potential.

Additionally, increasing awareness among clinicians, investment in molecular diagnostics, and patient access programs enhance the feasibility of introducing targeted therapies for rare cancers. As a result, companies can expand their portfolios, address unmet medical needs, and tap into new revenue streams.

South and Central America Cancer Targeted Therapy Market Size and Share Analysis:

The South and Central America Cancer Targeted Therapy market demonstrates steady growth, with size and share analysis highlighting evolving trends and competitive dynamics among key players. The report examines subsegments categorized within therapy type, indication, and distribution channel, offering insights into their contribution to overall market performance.

By therapy type, the monoclonal antibodies subsegment dominated the market in 2024, driven by high efficacy in breast, lung, and colorectal cancers, and established clinical guidelines supporting their use.

Based on indication, the lung cancer subsegment dominated the market in 2024, driven by the high prevalence, environmental risk factors, and availability of multiple approved targeted therapies for EGFR, ALK, and PD-L1 mutations.

By distribution channel, the hospital pharmacies subsegment dominated the market in 2024, driven by targeted therapies that require clinical administration, monitoring, and cold-chain storage.

South and Central America Cancer Targeted Therapy Market Report Highlights:

South and Central America Cancer Targeted Therapy Market Report Coverage and Deliverables:

The "South and Central America Cancer Targeted Therapy Market Size and Forecast (2021–2031)" report provides a detailed analysis of the market covering below areas:

• South and Central America Cancer Targeted Therapy market size and forecast at regional and country levels for key segments covered under the scope
• South and Central America Cancer Targeted Therapy market trends, as well as market dynamics such as drivers, restraints, and key opportunities
• South and Central America Cancer Targeted Therapy market analysis covering key trends, regional framework, major players, regulations, and recent market developments
• Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the South and Central America Cancer Targeted Therapy market
• Detailed company profiles, including SWOT analysis

South and Central America Cancer Targeted Therapy Market Geographic Insights:

The geographical scope of the South and Central America Cancer Targeted Therapy market report is divided into: Brazil, Argentina, Peru, Chile, and Colombia. Brazil held the largest share in 2024.

Brazil is the largest market in South and Central America, driven by a combination of high cancer prevalence, advanced healthcare infrastructure in urban areas, and a growing focus on precision medicine. Hospital pharmacies and specialized oncology centers dominate distribution, while molecular diagnostic labs facilitate biomarker-guided therapy. Public and private hospitals implement reimbursement programs, and international pharmaceutical companies frequently conduct clinical trials in urban centers to enable early access to novel therapies. Argentina, Chile, and Colombia exhibit moderate adoption, with access concentrated in metropolitan hospitals. Clinical trials and public-private partnerships help expand the availability of monoclonal antibodies, immune checkpoint inhibitors, and tyrosine kinase inhibitors.

Insurance coverage and government programs increasingly support high-cost therapies, although rural regions face access and affordability challenges. Across South and Central America, hospitals remain the dominant end users, while retail pharmacies and specialty centers facilitate access to oral targeted therapies. Multinational companies such as Roche, Merck, AstraZeneca, Novartis, and Bristol-Myers Squibb maintain strong regional presence through partnerships, clinical trial participation, and education initiatives. The region's diverse healthcare infrastructure necessitates localized strategies, combining premium adoption in urban hospitals with affordability-focused approaches in emerging areas, making it a promising market for targeted oncology therapies.

South and Central America Cancer Targeted Therapy Market Research Report Guidance:

• The report includes qualitative and quantitative data in the South and Central America Cancer Targeted Therapy market across therapy type, indication, distribution channel, and geography.
• The report starts with the key takeaways (chapter 2), highlighting key trends and outlook of the South and Central America Cancer Targeted Therapy market.
• Chapter 3 includes the research methodology of the study.
• Chapter 4 includes ecosystem analysis.
• Chapter 5 highlights the major industry dynamics in the South and Central America Cancer Targeted Therapy market, including factors that are driving the market, prevailing deterrents, potential opportunities, as well as future trends. Impact analysis of these drivers and restraints is also covered in this section.
• Chapter 6 discusses the South and Central America Cancer Targeted Therapy market scenario, in terms of historical market revenues, and forecast till the year 2031.
• Chapters 7 to 11 cover South and Central America Cancer Targeted Therapy market segments by therapy type, indication, distribution channel, and geography across Brazil, Argentina, Peru, Chile, and Colombia. They cover the market revenue, forecast, and factors driving the market.
• Chapter 12 describes the competitive analysis along with the heat map analysis for the key players operating in the market.
• Chapter 13 describes the industry landscape analysis. It provides detailed descriptions of business activities such as market initiatives, new developments, mergers, and joint ventures globally, along with a competitive landscape.
• Chapter 14 provides detailed profiles of the major companies operating in the Cancer Targeted Therapy market. Companies have been profiled on the basis of their key facts, business descriptions, products, financial overview, SWOT analysis, and key developments.
• Chapter 15, i.e., the appendix, is inclusive of a brief overview of the company, a list of abbreviations, and a disclaimer.

South and Central America Cancer Targeted Therapy Market News and Key Development:

The South and Central America Cancer Targeted Therapy market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the key developments in the South and Central America cancer targeted therapy market are:

• In October 2025, the FDA granted accelerated approval to sunvozertinib (Zegfrovy) for adults with locally advanced or metastatic non‑small cell lung cancer harboring EGFR exon 20 insertion mutations. This approval marks a major advance for patients with this resistant mutation subtype, for whom therapy options were previously limited.
• In April 2025, the U.S. Food and Drug Administration granted approvals for several targeted immuno‑oncology combinations, reflecting rapid clinical progress in precision cancer care. Specific approvals included nivolumab (Opdivo) plus ipilimumab (Yervoy) for unresectable or metastatic hepatocellular carcinoma and for microsatellite‑instability‑high or mismatch repair‑deficient colorectal cancer, moving beyond single‑agent use into combination strategies that harness both immune activation and targeted inhibition to improve outcomes.

Key Sources Referred:

• World Health Organization (WHO)
• World Heart Federation (WHF)
• Organisation for Economic Cooperation and Development (OECD)
• The World Bank Group
• Worldometer
• The Lancet
• International Bar Association
• International Trade Administration